Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) had its price target hoisted by equities research analysts at HC Wainwright from $17.00 to $33.00 in a note issued to investors on Thursday, MarketBeat reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 103.20% from the company's previous close.
A number of other research firms also recently commented on ETON. B. Riley initiated coverage on Eton Pharmaceuticals in a research report on Friday, January 10th. They issued a "buy" rating and a $21.00 target price on the stock. Craig Hallum raised their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th.
Read Our Latest Stock Report on Eton Pharmaceuticals
Eton Pharmaceuticals Stock Up 10.8 %
Shares of Eton Pharmaceuticals stock traded up $1.58 during mid-day trading on Thursday, hitting $16.24. The stock had a trading volume of 684,451 shares, compared to its average volume of 349,815. The firm has a 50-day moving average of $12.59 and a two-hundred day moving average of $8.06. The firm has a market cap of $423.05 million, a P/E ratio of -73.82 and a beta of 1.38. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $16.62.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $54,000. Jane Street Group LLC purchased a new position in Eton Pharmaceuticals in the 3rd quarter valued at approximately $90,000. Renaissance Technologies LLC grew its stake in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company's stock worth $350,000 after acquiring an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals during the second quarter worth $362,000. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at $373,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.
About Eton Pharmaceuticals
(
Get Free Report)
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.
Featured Stories
Before you consider Eton Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.
While Eton Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
